Work

Abstract 2964: On-treatment changes in circulating tumor DNA (ctDNA) level as an early predictor of clinical outcome in the LOTUS randomized phase 2 trial of 1st-line ipatasertib (IPAT) + paclitaxel (PAC) for metastatic triple-negative breast cancer (mTNBC)

Year: 2018

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2018-2964

Authors: Matthew J. Wongchenko, Doron Lipson, Travis Clark, Mark Kennedy, Mandy Greene, Virginia Breese, Alyssa Tsiros, Sung-Bae Kim, Cristina Saura, Mafalda Oliveira, Jose Baselga, Amy V. Kapp, Wai Y. Chan, Stina M. Singel, Steven Gendreau, Rebecca Dent

Institutions: Genentech, Foundation Medicine (United States), Asan Medical Center, University of Ulsan, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Memorial Sloan Kettering Cancer Center, National Cancer Centre Singapore

Language: English

Topic: Cancer Genomics and Diagnostics

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2886717841

Cites:

Cited by: 2

Related to: 10